Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model.

Infection and Immunity
B E Menzies, D S Kernodle

Abstract

A nonhemolytic, nonlethal variant of Staphylococcus aureus alpha-toxin constructed via oligonucleotide-directed mutagenesis and containing a single amino acid substitution (H-35 to L) was used to immunize a rabbit. The resulting antiserum was cross-reactive with wild-type alpha-toxin and neutralized its hemolytic activity in vitro. Passive immunization of mice with rabbit antiserum conferred protection against lethal challenge with wild-type alpha-toxin and against acute lethal challenge with a high-alpha-toxin -producing S. aureus strain. H35L alpha-toxin may be useful as a protective immunogen in S. aureus vaccine studies.

References

Sep 1, 1979·Microbiological Reviews·M Rogolsky
Mar 1, 1976·Infection and Immunity·P Cassidy, S Harshman
Jan 1, 1992·Vaccine·D L Watson
Dec 1, 1991·Microbiological Reviews·S Bhakdi, J Tranum-Jensen
Jan 1, 1986·Toxicon : Official Journal of the International Society on Toxinology·S HarshmanR W Harrison
Jan 1, 1988·Methods in Enzymology·A W Bernheimer
Sep 1, 1988·The American Journal of Physiology·N SuttorpD Drenckhahn
Aug 1, 1988·The Journal of Experimental Medicine·S BhakdiL Roka
May 24, 1984·The New England Journal of Medicine·J N Sheagren

❮ Previous
Next ❯

Citations

Oct 14, 2005·Expert Review of Vaccines·Henry R Shinefield, Steven Black
Dec 12, 2007·Infection and Immunity·Timur O YarovinskyGary W Hunninghake
Jul 31, 2008·Expert Review of Vaccines·John R Middleton
Jan 25, 2011·Molecular Microbiology·Ashley L DumontVictor J Torres
Sep 4, 2014·Infection and Immunity·Sabine RauchDominique Missiakas
Apr 1, 2016·Clinical and Vaccine Immunology : CVI·Luigi FiaschiFabio Bagnoli
Nov 28, 2001·Current Infectious Disease Reports·Jean C. Lee
May 11, 2000·Proceedings of the National Academy of Sciences of the United States of America·S K MazmanianO Schneewind
Apr 22, 2009·Infection and Immunity·Brook E Ragle, Juliane Bubeck Wardenburg
Dec 4, 2009·Current Opinion in Critical Care·Samuel M Moskowitz, Jeanine P Wiener-Kronish
Jul 14, 2010·Proceedings of the National Academy of Sciences of the United States of America·Georgia A Wilke, Juliane Bubeck Wardenburg
Dec 24, 2008·Infection and Immunity·Xudong LiangYinduo Ji
Sep 18, 2009·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·A WackM Hilleringmann
Sep 12, 2014·The Journal of Biological Chemistry·Vaheh OganesyanWilliam F Dall'Acqua
Jan 1, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Feng TangBing Li
May 28, 2013·Clinical & Developmental Immunology·Andreas F-P Sonnen, Philipp Henneke
Jul 31, 2013·Toxins·Bryan J Berube, Juliane Bubeck Wardenburg
Feb 13, 2008·The Journal of Experimental Medicine·Juliane Bubeck Wardenburg, Olaf Schneewind
May 29, 2020·Antioxidants & Redox Signaling·Viktoria Rungelrath, Frank R DeLeo
Jul 15, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hwan Keun KimDominique Missiakas
Mar 26, 1998·FEMS Immunology and Medical Microbiology·M I GómezD O Sordelli
Jun 30, 2019·Toxins·Roger AstleyMichelle C Callegan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.